Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608534 | 0.87 | HDAC6 (0.60) | NR1I2BRD4FLT3HDAC1ALDH1A1 | |
| SCHEMBL1608848 | 0.85 | CYP11B1 (0.60) | FGFR1NR1I2BRD4FLT3HDAC1 | |
| SCHEMBL13508660 | 0.81 | CYP11B1 (0.57) | FGFR1BRD4FLT3HDAC1SMN1; SMN2 | |
| SCHEMBL30497301 | 0.80 | FGFR1 (0.56) | FGFR1HDAC1ALDH1A1LMNAHPGD | |
| SCHEMBL6169524 | 0.80 | KDM4E (0.55) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL30497324 | 0.79 | FGFR1 (0.54) | FGFR1KDM4CHDAC1F2F10 | |
| SCHEMBL7215799 | 0.78 | CYP11B1 (0.67) | BRD4RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL15399884 | 0.78 | HDAC1 (0.55) | NR1I2BRD4FLT3HDAC1PPARG | |
| SCHEMBL22547166 | 0.77 | MEN1 (0.51) | FGFR1BRD4FLT3HDAC1SMN1; SMN2 | |
| SCHEMBL29424766 | 0.77 | FGFR1 (0.49) | FGFR1BRD4FLT3HDAC1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | FGFR1 4154/4885NR1I2 1454/4885BRD4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.